DiagnoCure Acquires Samba Technologies

In a move to insure its future growth, DiagnoCure (Quebec City, Canada) has acquired the assets, customer lists, and intellectual property of Samba Technologies SARL (France).

The intellectual property includes digital imaging and information technology that will help DiagnoCure create new applications in cancer diagnostic immunoassays. Digital imaging is necessary for the automation of immunopathology assays, a requirement for clinical laboratories performing large-volume testing. Prior to the acquisition, Samba had been a partner with DiagnoCure in the automation of its bladder cancer immunoassay, ImmunCyt/uCyt+. Samba's products are currently found in cancer centers and pathology reference laboratories throughout Europe and North America.

No financial details were disclosed. In November 2003, DiagnoCure gave an exclusive worldwide license to Gen-Probe to use its PCA3 (DD3) technology in prostate cancer.

DiagnoCure specializes in the development, production, and commercialization of diagnostic tests for detecting cancer. Currently, the company is actively pursuing the development of a prototype test for lung cancer detection.




Related Links:
DiagnoCure
Samba